Approval · Notice of Compliance 17323 · 2015
EVOTAZ: Notice of Compliance 17323
Issued September 25, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17323
- Date
- September 25, 2015
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EVOTAZ | 02446731 | Cancelled Post Market |
Medicinal ingredients
- ATAZANAVIR SULFATE 300 MG per TAB
- COBICISTAT 150 MG per TAB